Literature DB >> 8164504

The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats.

K P Leow1, M T Smith.   

Abstract

The antinociceptive activity of noroxycodone (NOR) was determined and its potency compared with that of oxycodone (OXY) and morphine (MOR) after intracerebroventricular (icv) administration to Sprague-Dawley rats. The antinociceptive potencies of OXY and NOR relative to MOR were 0.44 and 0.17, respectively. Administration of naloxone (55 nmol icv) abolished the antinociceptive response produced by the subsequent administration of OXY (227 nmol icv), indicating that the antinociceptive effects of OXY are mediated by opioid receptors. In addition, the same dose of naloxone (55 nmol icv) markedly reduced the antinociceptive effects of NOR (332 nmol icv) and MOR (93 nmol icv) indicating the involvement of opioid receptors in the antinociceptive activities of NOR and MOR. NOR, administered by the icv route, also produced excitatory effects throughout the antinociceptive dose range, the severity of which was reduced but not abolished by prior administration of naloxone (55 nmol icv). As excitatory effects have not been observed in patients receiving OXY, it is unlikely that NOR contributes to the analgesic activity of OXY administered systemically to humans.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8164504     DOI: 10.1016/0024-3205(94)00849-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.

Authors:  Hannu Kokki; Ilpo Rasanen; Merja Lasalmi; Sanna Lehtola; Veli-Pekka Ranta; Kari Vanamo; Ilkka Ojanperä
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

3.  Pregnancy in a patient with congenital analbuminaemia.

Authors:  Hillary Hu; Roshini Nayyar; Lucinda Jean Berglund; Elizabeth Anne Anderson
Journal:  BMJ Case Rep       Date:  2017-02-02

4.  Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients.

Authors:  Takafumi Naito; Masaki Tashiro; Keisuke Yamamoto; Kazunori Ohnishi; Yoshiyuki Kagawa; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2012-03-23       Impact factor: 2.953

5.  Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.

Authors:  Lillian Huang; Stephen R Edwards; Maree T Smith
Journal:  Pharm Res       Date:  2005-07-29       Impact factor: 4.200

6.  Ventilatory responses of healthy subjects to intravenous combinations of morphine and oxycodone under imposed hypercapnic and hypoxaemic conditions.

Authors:  L A Ladd; P C Kam; D B Williams; A W E Wright; M T Smith; L E Mather
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

7.  In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.

Authors:  A Kuo; B D Wyse; W Meutermans; M T Smith
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 8.  Intractable restless legs syndrome: role of prolonged-release oxycodone-naloxone.

Authors:  Stefano de Biase; Mariarosaria Valente; Gian Luigi Gigli
Journal:  Neuropsychiatr Dis Treat       Date:  2016-02-23       Impact factor: 2.570

Review 9.  Pharmacogenomics of oxycodone: a narrative literature review.

Authors:  Nelly N Umukoro; Blessed W Aruldhas; Ryan Rossos; Dhanashri Pawale; Janelle S Renschler; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2021-03-17       Impact factor: 2.533

10.  CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.

Authors:  Ulrike M Stamer; Lan Zhang; Malte Book; Lutz E Lehmann; Frank Stuber; Frank Musshoff
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.